PKCβ inhibition decreases infarct volume and improves functional outcome. WT mice were given vehicle or the PKCβ inhibitor (PKCβi; 10 mg/kg) once a day for 3 days and then subjected to MCAO followed by 3 additional daily doses of the inhibitor. Infarct volume was assessed by using 2,3,5-triphenyltetrazolium chloride (TTC) staining at 72 hours (A) and 7 days (B) after MCAO. (C) Representative images of TTC staining 7 days after MCAO. (D) Functional outcome was measured by assessing the lateralized bias in the corridor test 7 days after MCAO. (E) Pearson’s correlation between the lateralized bias and infarct volume in vehicle- and PKCβi-treated mice, 7 days after MCAO. One-way analysis of variance followed by a Holm-Šídák post hoc test was used for comparison of ≥3 groups; a t test was used for comparison between 2 groups. **P < .01, ****P < .0001. Contra, contralateral; Ipsi, ipsilateral; ns, nonsignificant; Veh, vehicle.